This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib.
Richard S. Finn, MD
Advertisement
Articles by Richard S. Finn, MD
Advertisement
Latest Updated Articles
Second-Line Regorafenib Extends Survival in Sorafenib-Tolerant HCC PatientsPublished: January 21st 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
2
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
3
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
4
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
5
